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Tumor necrosis factor (TNF)-related activation-in-
duced cytokine (TRANCE), a member of the TNF family
expressed on activated T-cells, bone marrow stromal
cells, and osteoblasts, regulates the function of dendritic
cells (DC) and osteoclasts. The TRANCE receptor
(TRANCE-R), recently identified as receptor activator of
NF-kb (RANK), activates NF-kB, a transcription factor
critical in the differentiation and activation of those
cells. In this report we identify the TNF receptor-asso-
ciated factor (TRAF) family of signal transducers as
important components of TRANCE-R-mediated NF-kB
activation. Coimmunoprecipitation experiments sug-
gested potential interactions between the cytoplasmic
tail of TRANCE-R with TRAF1, TRAF2, TRAF3, TRAF5,
and TRAF6. Dominant negative forms of TRAF2, TRAF5,
and TRAF6 and an endogenous inhibitor of TRAF2,
TRAF-interacting protein (TRIP), substantially inhib-
ited TRANCE-R-mediated NF-kB activation, suggesting
a role of TRAFs in regulating DC and osteoclast func-
tion. Overexpression of combinations of TRAF dominant
negative proteins revealed competition between TRAF
proteins for the TRANCE-R and the possibility of a TRAF-
independent NF-kB pathway. Analysis of TRANCE-R de-
letion mutants suggested that the TRAF2 and TRAF5
interaction sites were restricted to the C-terminal 93
amino acids (C-region). TRAF6 also complexed to the
C-region in addition to several regions N-terminal to the
TRAF2 and TRAF5 association sites. Furthermore,
transfection experiments with TRANCE-R deletion mu-
tants revealed that multiple regions of the TRANCE-R
can mediate NF-kB activation.
TRANCE,1 also called RANKL (1), osteoclast differentiation
factor (2), and osteoprotegerin ligand (3), is a TNF family
ligand that regulates immune responses and bone remodeling.
TRANCE is highly expressed on antigen receptor-activated
T-cells and enhances the survival of dendritic cells (DC) prob-
ably, in part, by up-regulating Bcl-xL expression, implicating
TRANCE in T-cell-DC communication (4, 5). Furthermore,
TRANCE is expressed on osteoblasts/stromal cells stimulated
with vitamin D3, prostaglandin E2, IL-11, or glucocorticoids
and can induce osteoclast (OCL) differentiation and activation,
suggesting that TRANCE is the sought after link between
various known regulatory molecules and bone resorption (2, 3).
Members of the TNFR family and the IL-1 receptor associate
either directly or indirectly with TNF receptor-associated fac-
tors (TRAFs), adaptor proteins that recruit and activate down-
stream signaling transducers (6). Generally, TRAFs are char-
acterized by an effector N-terminal RING finger/zinc finger
domain and a conserved C-terminal TRAF domain. The TRAF
domain is required for hetero- or homotypic interactions with
other TRAF proteins, interactions with receptors, and interac-
tions with downstream signal transducers. TRAF2, TRAF5,
and TRAF6 activate nuclear factor-kB (NF-kB) by signaling via
NF-kB-inducing kinase and IkB kinase-a and -b (7–11). Acti-
vated NF-kB enters the nucleus and induces the expression of
numerous genes including cytokines, adhesion molecules, and
anti-apoptotic regulators (12).
Currently, two receptors for TRANCE have been identified.
RANK (receptor activator of NF-kB) or TRANCE-R is a TNF
receptor family member most closely related to CD40 (1), an
important immunomodulatory molecule (13, 14). Although
TRANCE-R mRNA is ubiquitously expressed, the expression of
TRANCE-R protein appears to be limited to splenic, lymph
node, and bone marrow-derived dendritic cells (4), activated
T-cells,2 and osteoclast progenitors (3). The relatively large
cytoplasmic tail of TRANCE-R (aa 235–625) does not contain
any canonical signaling motifs implying that the signaling
machinery may involve adaptor proteins. Indeed, TRANCE-
induced activation of c-Jun N-terminal kinase (JNK) can be
inhibited in murine thymocytes overexpressing a dominant
negative TRAF2 adaptor protein (4). Osteoprotegerin (OPG/
OCIF), a secreted decoy receptor for TRANCE, inhibits
TRANCE-mediated osteoclast differentiation (2, 15, 16). Sys-
temic overexpression or injection of OPG causes osteopetrosis
in mice (15), whereas OPG deficiency results in osteoporosis
(17, 18). OPG is also a decoy receptor for TNF-related apopto-
sis-inducing ligands (TRAIL) and can neutralize its apoptosis-
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inducing effects (19), suggesting that TRANCE is part of a
complex cytokine network that coordinates an array of biolog-
ical processes.
The NF-kB family of transcription factors plays an important
role in DC and osteoclast function. Dendritic cell development
is inhibited in RelB-deficient mice (20) and in bone marrow
cultures infected with adenovirus harboring the IkB repressor
(21). NF-kB1 (p50) and NF-kB2 (p52) double knockout mice
develop osteopetrosis because of a defect in osteoclast differen-
tiation (22). In addition, IL-1 enhances OCL survival by acti-
vating NF-kB (23). Therefore, discovering the mechanisms
leading to NF-kB activation from the TRANCE-R will aid in our
understanding of the molecular events involved in DC and
osteoclast function. Our results demonstrate that TRANCE-R
associates with TRAF2, TRAF5, and TRAF6 at distinct regions
of the cytoplasmic tail to initiate NF-kB activation. Therefore,
TRANCE may direct DC and OCL differentiation and activa-
tion through the TRANCE-R by stimulating NF-kB via TRAFs.
MATERIALS AND METHODS
Constructs—TRAF5.DN (aa 236–559) and TRAF6.DN (289–522)
open reading frames (ORFs) were amplified by PCR and subcloned into
pcDNA3.1 (Invitrogen, Carlsbad, CA) containing a 39-hemagglutinin
(HA) tag. A PCR product encoding TRAF2.DN (241–501) was cloned
into pcDNA3.1 containing a 39-1D4 tag. The HA-TRAF1, TRAF2, HA-
TRIP, and HA-hTRADD expression vectors were previously described
(24). pBABE/HA-TRAF3 (25) was kindly provided by Dr. Genhong
Cheng (UCLA, Los Angeles, CA). FLAG-TRAF5, FLAG-TRAF6, and
FLAG-hKi-67 (hKi) expression vectors were constructed by cloning the
ORF derived by PCR into the pFLAG-CMV-2 vector (pFLAG-2; Kodak,
Rochester, NY). The various TRANCE-R cytoplasmic tails (aa 235–625,
235–603, 235–559, 235–358, 532–625, and 354–536) were obtained by
reverse transcription-PCR of murine thymus RNA. The cytoplasmic
tails were fused to the 39 end of GST in pEBG (GST-TRcyt and GST-
TRcyt mutants) or the 39 end of the TRANCE-R extracellular/trans-
membrane domain (TR-E) in pFLAG-CMV-1 (pFLAG-1; Kodak). The
c-Jun (pFA-Jun) and Elk-1 (pFA-Elk1) pathway-specific transactiva-
tors, the GAL4 UAS-containing luciferase reporter (pFR-Luc) plasmid,
and the MEKK (pFC-MEKK) and MEK1 (pFC-MEK1) expression vec-
tors were purchased from Stratagene (La Jolla, CA). The NF-kB re-
porter vector (kB)3-interferon-luciferase and pCMV-b-gal plasmids (In-
vitrogen) were described previously (26). All constructs were made from
mouse ORFs unless indicated. ORFs obtained by PCR were confirmed
by DNA sequencing.
Transfections and Reporter Assays—293T cells were grown under
standard conditions (Dulbecco’s modified Eagle’s medium, 10% fetal
bovine serum, 37 °C, 5% CO2). One day prior to transfection cells were
split into 6-well dishes (4 3 105/well) coated with 0.1% gelatin for
luciferase assays or in 10-cm dishes (2 3 106/well) for interaction
assays. The various reporter and expression vectors were transfected by
the calcium phosphate precipitation method as described previously
(26). The amount of transfected DNA was kept constant with pcDNA3.1
plasmid. 24–36 h after transfection, the cells were harvested and sub-
jected to luciferase and b-galactosidase assays as described previously
(26). Measurements of luciferase were normalized to b-galactosidase
activity and expressed as a ratio to values obtained from cells treated
with vector alone.
Interaction Assays—293T cells transfected with GST-TRcyt, GST-
TRcyt mutants, or potential interacting proteins were harvested 24–36
h after transfection, treated with lysis buffer (0.1% Nonidet P-40, 300
mM NaCl, 100 mM KCl, 1 mM EDTA, 10 mM HEPES, pH 7.5), cleared by
centrifugation, and mixed together as indicated in the figure legends.
After incubation (4 °C, 2 h) the complexes were isolated with glutathi-
one-Sepharose, washed 3–4 times with lysis buffer, subjected to SDS-
PAGE, and transferred to membranes. Western blot analyses were
performed with either a-TRAF2 (Santa Cruz Biotechnology, Santa
Cruz, CA), a-HA (12CA5), or a-FLAG Ab (M2, Kodak). For coexpres-
sion-interaction assays, cells were cotransfected with GST-TRcyt with
the various TRAFs. The transfectants were lysed and analyzed by
Western blotting using the conditions described above.
RESULTS AND DISCUSSION
Overexpression of TRANCE-R Activates c-Jun, Elk-1, and
NF-kB—c-Jun and NF-kB activation by the murine TRANCE-R
was examined in 293T cells to determine whether an overex-
pression system in tumor cell lines could accurately model
TRANCE-R signaling. Activation of the ETS domain-contain-
ing transcription factor Elk-1 was also examined because it is a
substrate for the mitogen-activated protein kinases (MAPK):
JNK, p38, and extracellular signal-regulated kinase (ERK),
which are often activated by TNFR family members. In addi-
tion, Elk-1 regulates the expression of c-Fos, a transcription
factor important for osteoclast differentiation (27). An epitope-
tagged murine TRANCE-R expression vector was cotransfected
with luciferase reporter constructs that monitor either c-Jun,
Elk-1, or NF-kB transcriptional activity. Fig. 1 demonstrates
that overexpression of TRANCE-R induced c-Jun (;3-fold; Fig.
1A), Elk-1 (;5-fold; Fig. 1B), and NF-kB (;100-fold; Fig. 1C)
when compared with cells transfected with vector alone. As
expected a mutant TRANCE-R lacking the cytoplasmic tail
(TR-E) failed to activate c-Jun, Elk-1, or NF-kB. MEKK,
MEK1, and TRAF2 expression provided positive controls for
c-Jun, Elk-1, and NF-kB activation, respectively. A dose-re-
sponse curve showed that 50 ng of TRANCE-R expression
vector was sufficient for achieving maximal NF-kB activation
(data not shown).
The TRANCE-R Cytoplasmic Tail Associates with TRAF
Adaptor Proteins—Immunoprecipitation experiments were
performed to test the association of TRANCE-R with all the
known TRAF proteins except for TRAF4, which was shown to
be a nuclear protein (28). The association of TRAF1, TRAF3,
TRAF5, and TRAF6 with the cytoplasmic tail of TRANCE-R
fused to GST (GST-TRcyt) was observed when coexpressed in
293T cells (data not shown). However, TRAF2 could not be
analyzed by coexpression because it prevented high levels of
expression of GST-TRcyt for unknown reasons (data not
shown). Therefore, lysates from 293T cells overexpressing GST
or GST-TRcyt were mixed with lysates from 293T cells overex-
pressing either TRAF1, TRAF2, TRAF3, TRAF5, TRAF6, hu-
man TRADD (hTRADD), or hKi-67 (hKi). GST-TRcyt-interacting
protein complexes were isolated with glutathione-Sepharose
FIG. 1. TRANCE-R (TR) induces c-Jun, Elk-1, and NF-kB acti-
vation. 293T cells were transfected with 500 ng/well pFLAG-1 (Vec),
pFLAG-1/TRANCE-R (TR), and pFLAG-1/TR-Ecto (TR-E), which con-
tains only the extracellular/transmembrane region of TRANCE-R or
plasmids expressing various known activators (MEKK, MEK1, or
TRAF2). c-Jun (A) and Elk-1 (B) transcriptional activity was monitored
with a pathway-specific trans-activator plasmid encoding a GAL4 DNA-
binding domain fused to either c-Jun or Elk-1 activator domains and a
GAL4 UAS/luciferase reporter construct. C, NF-kB activity was meas-
ured with a (kB)3-interferon luciferase reporter plasmid as described
previously (26). Vectors encoding b-galactosidase were cotransfected in
every sample to normalize transfection efficiencies and subsequent
manipulations. After transfection (24–36 h), cells were harvested, ly-
sed, and analyzed for luciferase and b-galactosidase activity. Luciferase
values were normalized to b-galactosidase activity, and the results are
displayed as a -fold induction over vector alone. A representative result
of three independent experiments is shown. Error bars denote standard
deviations between samples performed in triplicate.














beads and visualized by Western analysis. Ten percent of the
lysates used for each immunoprecipitation were analyzed to
confirm the expression of potential TRANCE-R-interacting
proteins. TRAF1, TRAF2, TRAF3, TRAF5, and TRAF6 but not
hTRADD or hKi associated with GST-TRcyt but did not inter-
act with GST alone (Fig. 2).
TRAF1 recruits cellular inhibitors of apoptosis to the recep-
tor complex (29), and overexpression of TRAF1 inhibits T-cell
receptor-mediated cell death of CD81 T-cells (30). Therefore,
TRAF1 may partially mediate TRANCE-induced DC survival.
TRAF2, TRAF5, and TRAF6, in addition to NF-kB activation,
are responsible for JNK induction leading to Jun/Fos activator
protein-1 (AP-1) transactivational activity. TRAF6 also stimu-
lates ERK (31), which phosphorylates and activates a distinct
set of transcription factors including c-Myc, Elk-1, C/EBP,
Tal-1, and ATF-2. MAPK-induced transcriptional activity may
integrate with the NF-kB pathway to mediate the various
effects of TRANCE on DC and osteoclasts.
Dominant Negative Forms of TRAF2, TRAF5, and TRAF6
Suppress TRANCE-R-mediated NF-kB Activation—The direct
evidence implicating NF-kB in DC and OCL development and
function prompted a focused examination of its mechanism of
activation by TRANCE-R. The requirement of TRAFs for
TRANCE-R-mediated NF-kB activation was tested using vec-
tors that encode for the TRAF dominant negative (TRAF.DN)
mutants: TRAF2.DN (aa 241–501), TRAF5.DN (aa 236–559)
and TRAF6.DN (aa 289–522). These mutants lack the RING
and/or zinc finger effector domains and suppress signaling by
interacting with the receptor and preventing the activation of
specific endogenous TRAF molecules (32). Coexpression of
TRANCE-R with increasing amounts of either TRAF2.DN,
TRAF5.DN, or TRAF6.DN resulted in a dose-dependent inhi-
bition of NF-kB activation (Fig. 3). However, NF-kB induction
was incompletely blocked despite a 20-fold excess of any of the
vectors encoding TRAF.DN proteins. TRIP, a TRAF2-interact-
ing protein that inhibits TRAF2-dependent NF-kB activation
(24), also decreased NF-kB activation by the TRANCE-R in a
dose-dependent manner. In contrast, overexpression of an ir-
relevant protein, human autoimmune antigen Ki-67 (hKi),
failed to inhibit TRANCE-R-mediated NF-kB activation, thus
indicating the specificity of TRAF.DN and TRIP proteins.
Therefore, NF-kB activation induced by the TRANCE-R signal-
ing is, in part, mediated by TRAF2, TRAF5, and TRAF6 and
can be negatively regulated by TRIP.
Functional and Biochemical Mapping of the TRANCE-R Cy-
toplasmic Tail—Deletion mutants of the TRANCE-R cytoplas-
mic tail (Fig. 4A) were fused with GST (GST-TR) or with the
FLAG-tagged extracellular transmembrane domain of
TRANCE-R (TR-E). The design of TRANCE-R cytoplasmic tail
deletions was based on PXQE(T/S) or VXX(T/S)XEE TRAF-
binding sites determined in other TNFR family members (26,
33). The cytoplasmic tail was arbitrarily divided into a mem-
brane-proximal N-terminal region (N-region; aa 235–358), a
middle region (M-region; aa 359–531), and a C-terminal region
(C-region; aa 532–625). Associations between GST-TR mutants
and TRAF2, TRAF5, and TRAF6 were examined. Lysates from
293T cells overexpressing TRAF proteins were mixed with
lysates containing the different GST-TR fusion proteins, and
GST-TR/TRAF complexes were precipitated with glutathione-
Sepharose and analyzed by Western blot. These membranes
were also stained with Coomassie brilliant blue to confirm the
presence of the GST-TR proteins. TRAF2 associated most
strongly with GST-TR-235–625, -235–603, -235–559, and
-532–625, weakly with -354–536, but not with -235–358 (Fig.
4B). These results suggest that amino acid residues 532–559
contain the major TRAF2-interacting site. Similar reasoning
suggested that residues 559–603 of the C-region were required
for TRAF5 binding (Fig. 4B). Therefore, both TRAF2 and
TRAF5 associate with the TRANCE-R at distinct but juxta-
posed sites within the C-region. TRAF6 associated with the
N-region and M-region containing mutants but less efficiently
to the C-region (Fig. 4B). Thus TRAF6 can associate with
FIG. 2. TRANCE-R associates with the TRAF family of adaptor
proteins. Lysates of 293T cells overexpressing the cytoplasmic tail of
TRANCE-R (aa 235–625) fused to GST (GST-TRcyt) were mixed with
lysates from 293T cells expressing HA-TRAF1 (TRAF1), TRAF2, HA-
TRAF3 (TRAF3), FLAG-TRAF5 (TRAF5), FLAG-TRAF6 (TRAF6), HA-
hTRADD (hTRADD), or FLAG-hKi-67 (hKi) as described under “Mate-
rials and Methods.” The GST-TRcyt-interacting protein complexes were
precipitated with glutathione-Sepharose beads, washed extensively in
lysis buffer, and analyzed by SDS-PAGE/Western blot analysis. 10% of
the input lysates were also analyzed to confirm the expression of the
putative interacting proteins (Input 0.1). TRAF1, TRAF3, and hTRADD
were detected with the a-HA monoclonal antibody (12CA5). TRAF2 was
detected with N-terminal a-TRAF2 polyclonal antibodies. TRAF5,
TRAF6, and hKi were detected with an a-FLAG monoclonal antibody
(M2). All associations were confirmed at least three times in independ-
ent experiments.
FIG. 3. Dominant negative TRAF2, TRAF5, and TRAF6 pro-
teins and TRIP inhibit TRANCE-R-mediated NF-kB activation.
pFLAG-1/TRANCE-R (TR; 50 ng) was cotransfected with increasing
amounts of expression vectors encoding murine TRAF2.DN,
TRAF5.DN, TRAF6.DN, TRIP, or human Ki-67 (hKi). After transfection
(24–36 h), the cells were harvested, and NF-kB-induced luciferase
activity was assessed as described in Fig. 1. The average -fold induction
observed in three independent experiments performed in duplicate is
shown. Error bars denote the standard error of the mean (S.E.) of the
three experiments.














multiple sites N-terminal to the C-region.
The various transmembrane-anchored cytoplasmic tails
were tested for their ability to activate NF-kB. Western blot
analysis using the a-FLAG antibody demonstrated comparable
levels of expression produced by the various TR-E-cytoplasmic
tail constructs (Fig. 4C). Fig. 4D shows that mutants TR-
E1235–603 and TR-E1235–559, which lack the C-terminal 22
and 66 aa, respectively, stimulated similar levels of NF-kB
activity compared with the wild-type TRANCE-R (TR-E1235–
625). In addition, TR-E1235–358, the mutant encompassing
the N-terminal region (N-region), and TR-E1354–536, the mu-
tant delimiting the middle region (M-region), also induced rel-
atively high levels of NF-kB activity. Unexpectedly, the C-
region mutant, TR-E1532–625, consistently elicited relatively
low, yet substantial, NF-kB activity (10–20-fold), whereas the
N-region and M-region, which primarily interacted with
TRAF6, generated significantly higher levels of NF-kB activity.
These results suggest that TRAF6, in addition to TRAF2 and
TRAF5, is an important NF-kB-inducing element in the
TRANCE-R signaling complex.
Competition between TRAF Members for the TRANCE-R Sig-
naling Complex—Combinations of TRAF.DN proteins were co-
expressed with TRANCE-R in an attempt to enhance the
NF-kB inhibition caused by individual dominant negatives.
Expression of TRAF2.DN or TRAF6.DN in combination with
TRAF5.DN did not cause a further decrease in TRANCE-R-
mediated NF-kB activation compared with any TRAF.DN alone
(Fig. 5). However, TRAF2.DN in combination with TRAF6.DN
reduced NF-kB activity by an additional ;50% of the activity
observed with TRAF2.DN or TRAF6.DN alone. Addition of
TRAF2, TRAF5, and TRAF6 dominant negative proteins to-
gether did not inhibit NF-kB further than that observed with
TRAF2.DN plus TRAF6.DN. Conceivably, TRAF2 may com-
pete with TRAF5 by concealing residues important for its as-
sociation with the TRANCE-R. TRAF6 may also hinder the
association of TRAF5 with the TRANCE-R in a similar manner,
although the proximity between the TRAF5 and TRAF6 asso-
FIG. 4. Structure-function analysis of the TRANCE-R. A, dia-
gram of deletion mutants of the TRANCE-R cytoplasmic tail (TRcyt). N
and C denote the N and C termini, respectively. The amino acid se-
quence of potential TRAF-interacting motifs and their locations relative
to the various TRANCE-R mutants (thin lines) are shown. The N-
regions (aa 235–358), M-regions (aa 359–531), and C-regions (aa 532–
625) are indicated with thick lines. B, association of TRAF2, TRAF5,
and TRAF6 with GST-TRcyt mutants. Lysates from 293T cells trans-
fected with plasmids expressing GST-TRcyt (aa 235–625) and GST-
TRcyt mutants were combined with lysates from 293T cells transfected
with TRAF2, FLAG-TRAF5 (TRAF5), or FLAG-TRAF6 (TRAF6). Pro-
tein complexes were precipitated with glutathione-Sepharose and ana-
lyzed by SDS-PAGE/Western blot analysis. 10% of the lysates from
293T cells overexpressing TRAF proteins (Input 0.1) were analyzed to
confirm their expression and compare relative binding efficiencies. Af-
ter Western analysis, the blots were stained with Coomassie brilliant
blue (CBB) to verify the expression of wild-type or mutant GST-TR
expression. The bands corresponding to the various GST-TR proteins
are labeled with asterisks (*). Results from experiments that failed to
express high levels of wild-type or mutant GST-TRs in any sample were
discarded. Similar results were obtained from three independent exper-
iments. C, Western blot analysis (a-FLAG Ab) of 293T cells transfected
with constructs (0.5 mg) encoding the TRANCE-R extracellular/trans-
membrane domain (TR-E) fused to the various cytoplasmic tails as
described in Fig. 1. Bands corresponding to the various TR-E fusion
proteins are labeled with asterisks (*). D, NF-kB-dependent luciferase
activity measured from 293T cells 24–36 h after transfection with the
various TR-E fusion constructs (0.5 mg). A representative result of five
independent experiments is shown. Error bars denote standard devia-
tions of conditions performed in triplicate.
FIG. 5. Evidence of TRAF competition for the TRANCE-R and
a novel NF-kB-inducing signaling pathway. pFLAG-1/TRANCE-R
(TR; 50 ng) was cotransfected with combinations of vectors encoding
either TRAF2.DN, TRAF5.DN, or TRAF6.DN (1 mg). NF-kB-induced
luciferase expression was measured 24–36 h after transfection as de-
scribed in Fig. 1. A representative result from three independent ex-
periments is shown. Error bars indicate the standard deviations be-
tween samples performed in triplicate.














ciation sites was not resolved. Residual NF-kB activity (;10–
20-fold induction) could not be inhibited despite coexpression of
TRAF2.DN, TRAF5.DN, and TRAF6.DN together. Thus simi-
larly to CD30 (34, 35), TRANCE-R may initiate TRAF-inde-
pendent pathways or interact with unknown TRAFs to activate
NF-kB.
In this report we demonstrate that TRAF adaptor proteins
can associate with the cytoplasmic tail of TRANCE-R and me-
diate NF-kB activation. During the review of this article a
study was published showing associations between the human
TRANCE-R and TRAFs (36). However, in that study, the C-
terminal 86 residues (aa 530–616) were shown to be essential
for NF-kB activation and TRAF interaction whereas our data
define other regions capable of those functions. It is possible
that the human receptor has distinct properties compared with
the mouse receptor used in this study. More likely, however,
the discrepancies reflect the sensitivities of the different meth-
ods employed to study protein interactions or NF-kB activation.
TRAFs may be responsible for some of the effects of TRANCE
on DC and osteoclasts. Perhaps TRAFs via NF-kB and/or
MAPKs are linked to the expression of anti-apoptotic genes
such as bcl-xL or genes involved in differentiation and activa-
tion. The importance of TRAFs in TRANCE-R signaling in DC
or OCL will be further explored with TRAF-deficient mutant
mice or by overexpressing TRAF.DN proteins in those cells.
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